Inhibitor eradication and treatment for acquired hemophilia A

M Franchini, D Focosi - Expert Review of Hematology, 2024 - Taylor & Francis
ABSTRACT Introduction Acquired hemophilia A (AHA) is a rare hemorrhagic autoimmune
disorder characterized by autoantibodies against coagulation factor VIII (FVIII). In …

Single‐dose rituximab plus glucocorticoid versus cyclophosphamide plus glucocorticoid in patients with newly diagnosed acquired hemophilia A: A multicenter, open …

PJ Wang, R Zhou, F Xue, H Zhou, J Bai… - American Journal of …, 2024 - Wiley Online Library
Acquired hemophilia A (AHA) is a rare but serious bleeding disorder. Randomized
controlled trial (RCT) comparing the efficacy of immunosuppression therapy for AHA lacks …

Genetics and Epigenetics in Acquired Hemophilia A: From Bench to Bedside

N Evangelidis, N Kotsiou, P Evangelidis… - Current Issues in …, 2024 - mdpi.com
Acquired hemophilia A (AHA) is a bleeding disorder characterized by the immunological
inhibition of factor VIII (FVIII) of the hemostatic pathway leading to hemorrhagic events …

Mice possess a more limited natural antihuman factor VIII antibody repertoire than humans that is produced disproportionately by marginal zone B cells

M Cormier, E Burnett, A Mo, C Notley, N Tijet… - Journal of Thrombosis …, 2024 - Elsevier
Background One-third of patients with severe hemophilia A develop neutralizing antibodies
to the factor VIII (FVIII) protein in response to intravenous replacement therapy. Patients may …

[PDF][PDF] Case Report: Effective management of adalimumab-induced acquired hemophilia A with the CyDRI protocol

A Ceglédi, Á Bátai, J Dolgos, M Fekete… - Pathology and …, 2024 - por-journal.com
Methods: We conducted a retrospective analysis of the medical records of a 68-year-old
male patient who presented with adalimumabinduced AHA. Results: The patient received …

Innovative Therapies for Acquired Hemophilia A

M Franchini, D Focosi - Seminars in Thrombosis and …, 2024 - thieme-connect.com
Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder which can be life-
threatening. AHA is due to autoantibodies against coagulation factor VIII. Disease onset may …

Emicizumab for acquired hemophilia A: Report of two cases and dosing strategies

F Ahmed, M Kasianchyk, A Moreno, S Chang… - Ejhaem, 2024 - Wiley Online Library
Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder caused by
autoantibodies against FVIII. Severe AHA is life‐threatening. Currently, licensed hemostatic …

[HTML][HTML] Characteristics and outcome of a territory-wide cohort study of patients with acquired hemophilia A in Hong Kong

C Sin, THS Li, K Wong, K Wong, Y Sin, WK Lam… - Thrombosis …, 2024 - Elsevier
Abstract Introduction Acquired hemophilia A (AHA) is a rare bleeding disorder with
destruction of factor VIII by autoantibodies. Comprehensive data for Chinese patients are …

Acquired haemophilia A in paediatric patients: A retrospective French cohort of eight cases

P Mouthon, A Guy, R d'Oiron… - British Journal of …, 2024 - Wiley Online Library
Acquired haemophilia A (AHA) is a rare haemorrhagic disease characterised by new‐onset
haemorrhagic symptoms associated with a dramatic decrease in factor VIII levels and an anti …

Acquired hemophilia A: a single-center study of 165 patients

D Yu, F Xue, X Liu, Y Chen, R Fu, T Sun, X Dai… - Research and Practice …, 2024 - Elsevier
Abstract Introduction Acquired hemophilia A (AHA) is a rare hemorrhagic disorder caused by
factor VIII (FVIII) inhibitors. The diagnosis and management of AHA remains challenging …